利福平联合阿奇霉素治疗难治性肺炎支原体肺炎临床疗效研究
|
摘要
目的观察和研究难治性肺炎支原体肺炎(RMPP)应用利福平联合阿奇霉素治疗的临床效果。方法选取2013年7月~2015年1月收治的78例难治性肺炎支原体肺炎患儿,采用随机分组法分为对照组(n=39)和观察组(n=39),对照组患儿给予阿奇霉素治疗,给予10mg/kg阿奇霉素+250m L生理盐水静脉滴注,观察组患儿给予阿奇霉素联合利福平治疗,在对照组基础上给予10mg/kg利福平口服治疗,观察和比较两组患者临床治疗效果,总结临床治疗有效方案。结果观察组患儿临床治疗总有效率为94.87%,较对照组患儿总有效率82.05%显著提高(P<0.05);观察组患儿退热时间、咳嗽症状消失时间、肺部体征消失时间、住院时间分别为(3.53±1.11)d、(4.11±1.22)d、(14.34±2.82)d、(9.76±2.21)d,与对照组患儿(5.68±1.56)d、(6.59±1.75)d、(17.89±4.63)d、(12.45±3.76)d比较,差异具有统计学意义(P<0.05);观察组患儿不良反应发生率为10.26%,与对照组患儿不良反应发生率12.82%比较差异无统计学意义(P>0.05)。结论针对小儿难治性肺炎支原体肺炎患者,采用利福平与阿奇霉素联合治疗,有利于改善临床症状,缩短体温恢复时间,促进炎症吸收,减轻患儿不适感,不良反应少,安全可靠性高,有效提高临床治疗效果,提升患儿生活质量,促进其健康成长。
Objective To observe and study the clinical effect of rifampicin combined azithromycin in the treatment of refractory mycoplasma pneumoniae pneumonia(RMPP). Methods 78 children patients with RMPP, who were received in the hospital from July 2013 to January 2015, were selected and were randomly divided into control group and observation group, with 39 cases in each group. Children patients in control group were treated with intravenous drip 10mg/kg azithromycin and 250 m L saline, and children patients in observation group were treated with oral 10mg/kg rifampicin based on control group. To observe and compare the clinical effect between the two groups, to summarize the feasible schemes on clinical treatment. Results The total effective rate of clinical treatment in observation group(94.87%) was significantly higher than which in control group(82.05%), the differences was statically significant(P < 0.05). The defervescence time, the symptom disappearance time of cough, the disappearance time of pulmonary signs, the hospitalization time in observation group[(3.53±1.11)d,(4.11±1.22)d,(14.34±2.82)d,(9.76±2.21)d] were statically significant compared with which in control group[(5.68±1.56)d,(6.59±1.75)d,(17.89±4.63)d,(12.45±3.76)d](P < 0.05). The incidence of adverse reaction of children patients in observation group(10.26%) was no statistical significance compared with which in control group(12.82%)(P > 0.05).Conclusion Rifampicin combined azithromycin in the treatment of children patients with refractory mycoplasma pneumoniae pneumonia is propitious to improve the linical symptom, shorten the body temperature recovery time, promote the inflammation absorption, reduce the discomfortableness of children patients, has less adverse reaction, higher safety and reliability, could effectively improve the clinical treatment effect, improve the life quality of children patients, promote the healthy growth.
Objective To observe and study the clinical effect of rifampicin combined azithromycin in the treatment of refractory mycoplasma pneumoniae pneumonia(RMPP). Methods 78 children patients with RMPP, who were received in the hospital from July 2013 to January 2015, were selected and were randomly divided into control group and observation group, with 39 cases in each group. Children patients in control group were treated with intravenous drip 10mg/kg azithromycin and 250 m L saline, and children patients in observation group were treated with oral 10mg/kg rifampicin based on control group. To observe and compare the clinical effect between the two groups, to summarize the feasible schemes on clinical treatment. Results The total effective rate of clinical treatment in observation group(94.87%) was significantly higher than which in control group(82.05%), the differences was statically significant(P < 0.05). The defervescence time, the symptom disappearance time of cough, the disappearance time of pulmonary signs, the hospitalization time in observation group[(3.53±1.11)d,(4.11±1.22)d,(14.34±2.82)d,(9.76±2.21)d] were statically significant compared with which in control group[(5.68±1.56)d,(6.59±1.75)d,(17.89±4.63)d,(12.45±3.76)d](P < 0.05). The incidence of adverse reaction of children patients in observation group(10.26%) was no statistical significance compared with which in control group(12.82%)(P > 0.05).Conclusion Rifampicin combined azithromycin in the treatment of children patients with refractory mycoplasma pneumoniae pneumonia is propitious to improve the linical symptom, shorten the body temperature recovery time, promote the inflammation absorption, reduce the discomfortableness of children patients, has less adverse reaction, higher safety and reliability, could effectively improve the clinical treatment effect, improve the life quality of children patients, promote the healthy growth.
引文
[1]郭燕容,孔伟清,陈结仪,等.用阿奇霉素联合利福平治疗小儿难治性支原体肺炎的效果分析[J].当代医药论丛,2015,12(1):292-293.
[2]刘冬梅.观察利福平联合阿奇霉素治疗小儿难治性支原体肺炎疗效[J].中西医结合心血管病电子杂志,2014,5(2):78-80.
[3]严平.阿奇霉素联合头孢曲松钠治疗40例小儿难治性肺炎支原体肺炎的临床疗效观察[J].现代诊断与治疗,2014,25(20):4664-4665.
[4]曹焕珍,闫建华,简少霞,等.儿童难治性肺炎支原体肺炎16例临床分析[J].中国医师进修杂志,2012,35(22):71-73.
[5]杜占申.难治性肺炎支原体肺炎治疗体会[J].吉林医学,2011,32(17):3457-3458.
[6]崔赛男,谷丽,何凡,等.阿奇霉素联合头孢曲松钠治疗儿童难治性肺炎支原体肺炎疗效观察[J].世界临床药物,2012,33(12):743-747.
[7]侯丽洁.阿奇霉素联合头孢曲松钠治疗儿童难治性肺炎支原体肺炎疗效观察[J].医药前沿,2013,9(33):163-164.
[8]吴亚军,甘凯.儿童难治性肺炎支原体肺炎36例临床分析[J].中国处方药,2015,11(3):103-104.
[9]崔占杰,侯秀玲.利福平联合大环内酯类抗生素治疗肺炎支原体肺炎疗效观察[J].临床合理用药杂志,2014,21(26):37-38.
[10]樊国群.红霉素联合阿奇霉素治疗小儿支原体肺炎的疗效观察[J].吉林医学,2013,34(24):4935-4935.
[11]朱冰,陈维宪,李敏妍.阿奇霉素联合孟鲁司特钠治疗小儿肺炎支原体肺炎的疗效及其对血清C反应蛋白水平的影响[J].临床和实验医学杂志,2015,14(1):41-43.
[12]侯伟.用阿奇霉素联合地塞米松治疗儿童难治性支原体肺炎的疗效分析[J].当代医药论丛,2014,14(18):154-155.
[13]施婉文,王戈.阿奇霉素联合利福平治疗儿童支原体肺炎的研究[J].现代养生,2014,11(5):73-74.
[14]王健容,汪培勤.小儿难治性肺炎支原体肺炎34例诊治分析[J].现代诊断与治疗,2012,23(9):1366-1367.
[15]秦小菀,杨红.利福平辅助治疗难治性支原体肺炎疗效分析[J].中国实用医药,2011,6(11):198-199.
[16]谢金秋,陈莹.利福平辅助治疗难治性肺炎支原体肺炎疗效观察[J].中外医疗,2014,9(10):108-109.
[17]户波,毋英超.普米克令舒联合阿奇霉素治疗102例儿童肺炎支原体感染的疗效观察[J].中国医学创新,2015,13(4):38-40.
[2]刘冬梅.观察利福平联合阿奇霉素治疗小儿难治性支原体肺炎疗效[J].中西医结合心血管病电子杂志,2014,5(2):78-80.
[3]严平.阿奇霉素联合头孢曲松钠治疗40例小儿难治性肺炎支原体肺炎的临床疗效观察[J].现代诊断与治疗,2014,25(20):4664-4665.
[4]曹焕珍,闫建华,简少霞,等.儿童难治性肺炎支原体肺炎16例临床分析[J].中国医师进修杂志,2012,35(22):71-73.
[5]杜占申.难治性肺炎支原体肺炎治疗体会[J].吉林医学,2011,32(17):3457-3458.
[6]崔赛男,谷丽,何凡,等.阿奇霉素联合头孢曲松钠治疗儿童难治性肺炎支原体肺炎疗效观察[J].世界临床药物,2012,33(12):743-747.
[7]侯丽洁.阿奇霉素联合头孢曲松钠治疗儿童难治性肺炎支原体肺炎疗效观察[J].医药前沿,2013,9(33):163-164.
[8]吴亚军,甘凯.儿童难治性肺炎支原体肺炎36例临床分析[J].中国处方药,2015,11(3):103-104.
[9]崔占杰,侯秀玲.利福平联合大环内酯类抗生素治疗肺炎支原体肺炎疗效观察[J].临床合理用药杂志,2014,21(26):37-38.
[10]樊国群.红霉素联合阿奇霉素治疗小儿支原体肺炎的疗效观察[J].吉林医学,2013,34(24):4935-4935.
[11]朱冰,陈维宪,李敏妍.阿奇霉素联合孟鲁司特钠治疗小儿肺炎支原体肺炎的疗效及其对血清C反应蛋白水平的影响[J].临床和实验医学杂志,2015,14(1):41-43.
[12]侯伟.用阿奇霉素联合地塞米松治疗儿童难治性支原体肺炎的疗效分析[J].当代医药论丛,2014,14(18):154-155.
[13]施婉文,王戈.阿奇霉素联合利福平治疗儿童支原体肺炎的研究[J].现代养生,2014,11(5):73-74.
[14]王健容,汪培勤.小儿难治性肺炎支原体肺炎34例诊治分析[J].现代诊断与治疗,2012,23(9):1366-1367.
[15]秦小菀,杨红.利福平辅助治疗难治性支原体肺炎疗效分析[J].中国实用医药,2011,6(11):198-199.
[16]谢金秋,陈莹.利福平辅助治疗难治性肺炎支原体肺炎疗效观察[J].中外医疗,2014,9(10):108-109.
[17]户波,毋英超.普米克令舒联合阿奇霉素治疗102例儿童肺炎支原体感染的疗效观察[J].中国医学创新,2015,13(4):38-40.